Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A | P20648 | 4/20 | 0.45 |
| ▸ | ATP4B | P51164 | 4/20 | 0.45 |
| ▸ | VCP | P55072 | 1/20 | 0.43 |
| ▸ | PLAU | P00749 | 5/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CCR6 | P51684 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3607326 | 0.90 | MAPT (0.47) | ATP4AATP4BVCPPLAUMEN1 | |
| SCHEMBL3602268 | 0.81 | MAPT (0.56) | ATP4AATP4BPLAUMEN1KMT2A | |
| SCHEMBL2380032 | 0.81 | ATP4A (0.50) | ATP4AATP4BVCPPLAUHPGDS | |
| SCHEMBL3600274 | 0.81 | VCP (0.64) | ATP4AATP4BVCPHPGDSMEN1 | |
| SCHEMBL3597985 | 0.79 | ATP4A (0.61) | ATP4AATP4BPLAU | |
| SCHEMBL3599051 | 0.76 | SMN1; SMN2 (0.46) | ATP4AATP4BPLAUMEN1KMT2A | |
| Abafungin SCHEMBL29517947 | 0.73 | MEN1 (0.42) | VCPHPGDSMEN1KMT2AMAPT | |
| Abafungin SCHEMBL301669 | 0.73 | MEN1 (0.42) | VCPHPGDSMEN1KMT2AMAPT | |
| Abafungin SCHEMBL10455902 | 0.73 | MEN1 (0.41) | VCPHPGDSMEN1KMT2AMAPT | |
| SCHEMBL3612827 | 0.72 | ATP4A (0.47) | ATP4AATP4BVCPPLAUMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | claimed |
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | GRN, MAPT, GUCY1B1 | ATP4A 996/4885ATP4B 1107/4885VCP 1390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.